Agilent Invests in Cardiovascular Disease Research at Harvard Teaching Hospital

Jan 11, 2013
By LCGC Editors

Agilent Technologies (Santa Clara, California, USA) has selected Dr Robert Gerszten to receive the Agilent Thought Leader Award. Dr Gerszten is the director of clinical and translational research at Massachusetts General Hospital’s Institute for Heart, Vascular and Stroke Care (Massachusetts, USA). Founded in 1811, it is the largest teaching hospital of Harvard Medical School.

Gerszten is interested in identifying cardiovascular disease biomarkers and his research covers all aspects of basic molecular and cell biology, chemistry, mass spectrometry and bioinformatics. In recognition of his leadership in the field, Agilent will provide technical and scientific expertise, and personnel funding for his laboratory.

“Our goal is to identify new metabolites and proteins that mark disease activity, signal disease progression, and ultimately provide targets for therapeutic intervention,” said Gerszten. “We are grateful that Agilent supports our research and is helping us in our quest to advance translational cardiology.”

“Agilent is proud to support Dr Gerszten’s research in this pivotal project and further advance progress in the important field of cardiometabolic diseases,” said Agilent CTO Darlene Solomon, the executive sponsor of the award. “By providing support and cutting-edge technologies to leading translational researchers like Dr Gerszten, we aim to facilitate innovative research and to progress the fields of metabolomics and integrated biology toward improved patient outcomes.”

For more information please visit:

www.agilent.com